VANCOUVER, British Columbia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that its subsidiary, 3 Carbon Extractions Inc. (“3 CARBON”), has completed an exclusive marketing rights relationship with ExtractionTek Solutions Inc. (“ETS”) located in Denver, Colorado, U.S.
ETS is a recognized international leader in closed loop hydrocarbon extraction equipment. Their lines of closed loop extractors are designed for the safe and legal extraction of botanical materials utilizing propane, butane or blend of each. Since 2011, ETS has placed over 500 Closed Loop Hydrocarbon Extractors in the field. ETS is proud to offer three approved for market, closed loop extraction machines with industry leading processing speeds and simultaneously offering a wider range of runs sizes, than the rest. The-1300™, The Modular Extraction Platform™ (The MeP™), and The miniMeP™.
For more information about ETS, please visit their website: extractiontek.com
3 Carbon’s CEO Phillip Kwong said, “We are excited to be collaborating with one of the most highly-regarded extraction companies in the United States. We look forward to building on ETS’s track record of successful collaboration with clients and regulatory agencies as 3 Carbon prepares for the legalization of cannabis in Canada and the introduction of draft regulations over the coming year by Health Canada for edible cannabis products and derivatives.”
Veritas’ CEO, Dr. Lui Franciosi commented: “I am pleased to see 3 Carbon successfully secure exclusive marketing rights with ETS. Their solutions will enable 3 Carbon to provide Cannevert scientists with high quality, efficient extractions for products that we’re developing on the medicinal side.”
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 100% owned subsidiary Cannevert Therapeutics Ltd. (“CTL“), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by a strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion-dollar markets according to Deloitte’s Insights and Opportunities.
Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: veritaspharmainc.com
On behalf of the Board of Directors
"Dr. Lui Franciosi"
Dr. Lui Franciosi
President and Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.
Investor and Public Relations Contact
Veritas Pharma Inc.
The CSE has not reviewed, nor approved or disapproved the content of this press release.